HomeDNA • BMV
add
Ginkgo Bioworks Holdings Inc
Nakaraang pagsara
$262.00
Sakop ng taon
$164.00 - $770.40
Market cap
437.04M USD
P/E ratio
-
Dividend yield
-
Primary exchange
NYSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 48.32M | 27.34% |
Gastos sa pagpapatakbo | 124.26M | -39.90% |
Net na kita | -90.96M | 45.18% |
Net profit margin | -188.25 | 56.95% |
Kita sa bawat share | — | — |
EBITDA | -72.62M | 56.02% |
Aktuwal na % ng binabayarang buwis | -0.10% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 516.92M | -38.49% |
Kabuuang asset | 1.29B | -18.23% |
Kabuuang sagutin | 646.04M | 8.67% |
Kabuuang equity | 647.43M | — |
Natitirang share | 55.53M | — |
Presyo para makapag-book | 22.47 | — |
Return on assets | -16.47% | — |
Return on capital | -19.42% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -90.96M | 45.18% |
Cash mula sa mga operasyon | -51.52M | 42.28% |
Cash mula sa pag-invest | -198.68M | -1,540.66% |
Cash mula sa financing | -207.00K | 75.50% |
Net change in cash | -250.34M | -144.54% |
Malayang cash flow | -16.32M | 62.99% |
Tungkol
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
CEO
Itinatag
2008
Headquarters
Website
Mga Empleyado
834
